Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell expression profiling of whole B16F10 melanoma tumors, treated with PBS or DCP-IL-12/FLT3L.

ABSTRACT: Single cell expression profiling of whole B16F10 melanoma tumors, treated with PBS or DCP-IL-12/FLT3L.

PROVIDER: PRJNA947665 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23944160_1.fastq.gz	Fastqsanger.gz
	SRR23944160_2.fastq.gz	Fastqsanger.gz
	SRR23944161_1.fastq.gz	Fastqsanger.gz
	SRR23944161_2.fastq.gz	Fastqsanger.gz
	SRR23944162_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Single cell expression profiling of whole B16F10 melanoma tumors, treated with PBS or DCP-IL-12/FLT3L.

Project description:Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, and present antigens to T lymphocytes. They also generate cytokine and chemokine gradients that regulate immune cell trafficking, activation, and function. Monocyte-derived DCs (moDCs) pulsed with tumor antigens have been used as a platform for therapeutic vaccination in cancer. However, in spite of significant development and testing, antigen-loaded moDCs have delivered mixed clinical results. Here we present a DC therapy that uses a population of mouse or human DC progenitors (DCPs) engineered to produce two immunostimulatory cytokines, IL-12 and FLT3L. In the absence of antigen loading, cytokine-armored DCPs efficiently differentiated into conventional type I DCs (cDC1) and inhibited tumor growth in melanoma and autochthonous liver cancer models. Tumor response to DCP therapy involved synergy between IL-12 and FLT3L and was associated with early NK cell activation and massive effector T cell infiltration, robust M1-like macrophage programming, and ischemic tumor necrosis. Mechanistically, anti-tumor immunity was dependent on endogenous cDC1 expansion and interferon-γ (IFNγ) production and signaling, but did not require CD8+ T cell cytotoxicity. In one application, cytokine-armored DCPs synergized with antigen-specific CAR-T cells to eradicate intracranial gliomas in mice.

2023-09-19 | GSE228014 | GEO

TCR profiling of whole MC38 tumors, treated with PBS + IgG , Cis + PBS + aPD-1, Cis + DCP-IL-12/FLT3L + IgG or Cis + DCP-IL-12/FLT3L + ɑPD-1.

Project description:TCR profiling of whole MC38 tumors, treated with PBS + IgG , Cis + PBS + aPD-1, Cis + DCP-IL-12/FLT3L + IgG or Cis + DCP-IL-12/FLT3L + ɑPD-1.

| PRJNA948415 | ENA

TCR profiling of whole MC38 tumors, treated with PBS + IgG , Cis + PBS + aPD-1, Cis + DCP-IL-12/FLT3L + IgG or Cis + DCP-IL-12/FLT3L + ɑPD-1.

2023-09-19 | GSE228161 | GEO

Single-cell level gene expression profiles of immune cells within B16F10-OVA tumours treated with PBS or UDSP-Hep

Project description:Activation of the Alpha kinase 1 (ALPK1) is a promising strategy to be developed as a next-generation cancer immunotherapy. We used single cell RNA sequencing (scRNA-seq) to analyze the ALPK1 activation-triggered antitumour immune responses within the tumour microenvironment of B16F10-OVA tumours treated with PBS or UDSP-Hep.

2024-08-28 | GSE275540 | GEO

Effect of BMP2 on B16F10 melanoma cells

Project description:BMP2 treatment significantly reduces growth of B16F10 melanoma spheroids. This experiment analyses the transcriptome changes in B16F10 cells treated with or without BMP2.

2019-01-01 | GSE117074 | GEO

Comparison between CD103+ cDC1s from IL-33-treated Flt3L-BMDCs and GM-CSF-treated Flt3L-BMDCs

Project description:To assess genotypic differences between IL-33-induced CD103+ cDC1s and GM-CSF-induced CD103+ cDC1s IL-33 or GM-CSF was treated at 5 ng/ml on the day 5 of Flt3L-BMDC generation and then the cells were incubated for an additional 5 days Then, we performed RNA sequencing of CD103+ cDC1s isolated from IL-33 or GM-CSF-treated Flt3L-BMDCs

2023-05-30 | GSE226585 | GEO

Immunostimulatory effect of senescence in B16F10 melanoma cells

Project description:To investigate the effect of senescence induction on immunogical signatures in immunosuppresive B16F10 cells treated with the senescence inducer Doxorubicin

2022-10-18 | GSE212112 | GEO

RNAseq of B16F10 melanoma CD31+ cells

Project description:RNAseq of B16F10 melanoma CD31+ cells

| PRJNA606295 | ENA

RNAseq of B16F10 melanoma CD31+ cells

Project description:Intravasation, vascular dissemination and metastasis of malignant tumor cells require their passage over the vascular wall which is commonly composed of pericytes (mural cells) and the endothelial cell barrier. We currently decided to investigate the relative contribution of these cell types for B16F10 melanoma metastasis in mice using an experimental model of Shb gene inactivation. RNAseq of tumor endothelial cells from these mice revealed changes in cellular components such as adherens junctions and focal adhesions by gene ontology analysis that were in line with the observed effects on leakage and junction morphology.

2020-05-18 | GSE145201 | GEO

Effect of BMP2 on B16F10 melanoma cells

Project description:Effect of BMP2 on B16F10 melanoma cells

| PRJNA481005 | ENA